

# Clinical Outcomes After Hip Arthroscopy for Patients with Inflammatory Joint Disease: A Matched Control Study with Minimum 5-Year Follow-Up



**Ady H. Kahana-Rojkind, M.D.**

Fellow, American Hip Institute Research Foundation

# Disclosures

I (and/or my co-authors) have something to disclose.

Detailed disclosure information is available via:

AAOS Orthopaedic Disclosure Program on the AAOS  
website at

<http://www.aaos.org/disclosure>

# Background

- There is paucity in the literature regarding mid-term outcomes of primary hip arthroscopy who have pre-existing inflammatory joint diseases (IJD)

# Purpose


To present mid-term results of primary hip arthroscopy who have pre-existing (IJD)




We hypothesized that patients with IJDs undergoing hip arthroscopy would have significant postoperative improvement, but overall inferior outcomes compared to a benchmark control group

# Methods

February 2008-December 2018. Patients with IJD undergoing primary hip arthroscopy for the treatment of femoroacetabular impingement (FAI)



Patients with minimum five-year follow-up and preoperative IJD diagnoses were 1:3 matched to controls without IJD based on age at surgery, sex, BMI, labral treatment and Tonnis Grade. (n=27:81)



Patient-reported outcomes and rates of achieving clinically relevant thresholds were compared between the two groups.

# Results: Radiographic

Matched Demographic Information for IJD and Control Groups

	IJD	Control	P Value
Total Matched*	27	81	
Follow-up time, mo <sup>†</sup>	89.54 ± 28.41	64.87 ± 8.75	<0.01
Age at surgery, yr <sup>†</sup>	41.39 ± 13.97	42.37 ± 14.52	0.85
BMI (kg/m <sup>2</sup> ) <sup>†</sup>	25.71 ± 4.59	26.37 ± 5.79	0.86
Sex <sup>‡</sup>			
Male	4 (14.8%)	10 (17.5%)	>0.99
IJD Diagnosis <sup>‡</sup>			<0.01
Rheumatoid Arthritis	25 (92.59%)	0 (0%)	NA
Lupus	2 (7.41%)	0 (0%)	NA
DMARDs Prescribed <sup>‡</sup>	17 (62.96%)	0 (0%)	NA

\*The values are given as the number of cases.

<sup>†</sup>The values are given as the mean and standard deviation.

<sup>‡</sup>The values are given as number (percent)

# Results: Intra-Op

## Intraoperative Findings in IJD Patients and Controls

	IJD	Control	P Value
<b>Seldes Tear Type</b>			<b>&lt;0.05</b>
0	0 (0.0%)	3 (3.7%)	
1	8 (29.6%)	15 (18.5%)	
2	9 (33.3%)	50 (61.7%)	
1 & 2	10 (37.0%)	13 (16.0%)	
<b>ALAD Grade</b>			<b>0.16</b>
0	4 (14.8%)	5 (6.2%)	
1	6 (22.2%)	27 (33.3%)	
2	7 (25.9%)	30 (37.0%)	
3	8 (29.6%)	18 (22.2%)	
4	2 (7.4%)	1 (1.2%)	
<b>Acetabular Outerbridge</b>			<b>&lt;0.05</b>
0	3 (11.1%)	5 (6.2%)	
1	7 (25.9%)	27 (33.3%)	
2	7 (25.9%)	30 (37.0%)	
3	5 (18.5%)	17 (21.0%)	
4	5 (18.5%)	2 (2.5%)	
<b>Femoral Head Outerbridge</b>			<b>0.06</b>
0	15 (62.5%)	70 (86.4%)	
1	1 (4.2%)	0 (0.0%)	
2	2 (8.3%)	3 (3.7%)	
3	3 (12.5%)	3 (3.7%)	
4	3 (12.5%)	5 (6.2%)	

The IJD group more frequently had higher grade Seldes Type labral tears, higher grade Acetabular Outerbridge scores

# Patient-Reported Outcomes

	IJD	Control	P Value
<b>mHHS</b>			
Preoperative	59.01 ± 18.29	62.74 ± 13.50	0.34
Postoperative	73.43 ± 24.01	85.16 ± 16.51	<0.05
Preop vs postop P value	<0.05	<0.01	
<i>Improvement</i>	15.39 ± 23.71	22.04 ± 18.70	0.14
<b>NAHS</b>			
Preoperative	54.25 ± 20.42	63.83 ± 13.45	<0.05
Postoperative	74.95 ± 22.07	86.79 ± 13.75	<0.05
Preop vs postop P value	<0.05	<0.01	
<i>Improvement</i>	21.34 ± 21.12	22.75 ± 15.85	0.77
<b>HOS-SSS</b>			
Preoperative	39.12 ± 24.64	40.89 ± 20.03	0.62
Postoperative	57.13 ± 32.90	73.84 ± 28.95	<0.05
Preop vs postop P value	<0.05	<0.01	
<i>Improvement</i>	16.40 ± 32.64	31.51 ± 29.49	0.08
<b>VAS</b>			
Preoperative	5.35 ± 2.26	5.05 ± 2.21	0.91
Postoperative	3.58 ± 2.72	2.47 ± 2.57	0.07
Preop vs postop P value	<0.05	<0.01	
<i>Improvement</i>	-1.97 ± 2.49	-2.52 ± 3.11	0.23
<b>Satisfaction</b>	7.74 ± 2.38	8.21 ± 2.13	0.37

- The IJD and control group showed significant improvement at minimum 5-year follow-up

- The IJD group showed lower postoperative PRO scores



# Results: PROs

- For mHHS, NAHS and HOS-SSS, MCID and SCB was met at similar frequencies in the two groups.

For NAHS, the IJD group met PASS at lower frequencies in comparison to the control group.

## PASS and MCID

	IJD	Control	P Value
<b>MCID</b>			
mHHS	14 (60.9%)	61 (80.3%)	0.06
NAHS	16 (69.6%)	63 (82.9%)	0.16
HOS-SSS	12 (60.0%)	41 (73.2%)	0.27
<b>PASS</b>			
mHHS	15 (65.2%)	60 (78.9%)	0.18
NAHS	8 (34.8%)	48 (63.2%)	<0.05
HOS-SSS	8 (40.0%)	34 (60.7%)	0.11
<b>SCB</b>			
mHHS	6 (26.1%)	33 (43.42%)	0.136
NAHS	6 (26.1%)	35 (46.1%)	0.09
HOS-SSS	6 (26.1%)	29 (51.8%)	0.09

Values are presented as number (%). MCID, minimum clinically important difference; PASS, Patient Acceptable Symptom State; SCB, Substantial Clinical Benefit; mHHS, modified Harris Hip Score; NAHS, Non-Arthritic Hip Score; HOS-SSS, Hip Outcome Score-Sport Specific Subscale.

# Results: Survivorship

## Complications and Revisions

	IJD Group	Control Group	P Value
Second Hip Surgery*	6 (22.22%)	6 (7.41%)	<0.05
Open Gluteus Medius Repair*	0 (0%)	1 (1.23%)	>0.99
Revision Arthroscopy*	6 (22.22%)	5 (6.17%)	<0.01
Time to Second surgery, mo†	29.38 ± 5.42	35.70 ± 5.97	0.24
Conversion to THA*	7 (25.93%)	4 (4.94%)	<0.01
Time to conversion to THA, mo	55.74 ± 38.98	38.20 ± 28.05	0.46
Complications	0 (0%)	2 (2.47%)	>0.99

\*The values are given as number (percent).

†The values are given as the mean and standard deviation.

# Conclusion

- Patients with IJD undergoing hip arthroscopy demonstrate significant improvement in all PROs at minimum five-year Follow-up.
- Lower postoperative PROs, achieved clinically significant benchmarks less frequently.
- Higher rate of revision arthroscopy and conversion to arthroplasty with an odds ratio of 3.6 and 4.5 respectively



# Ady H. Kahana Rojkind

Comprehensive Hip Preservation Fellow

American Hip Institute Research Foundation

